We previously developed a stable form of galectin-9, an immunomodulatory animal lectin with a truncated linker peptide (G9Null), to overcome the protease sensitivity of wild-type galectin-9. G9Null is highly resistant to proteolysis, while the modification marginally improved the low solubility of the wild-type protein. To increase its solubility, we further modified the remaining linker region of G9Null. A 10-amino acid deletion with a single amino acid substitution resulted in an 400% increase in solubility and yield without an adverse effect on its biological activity. This mutant protein might be useful for largescale recombinant production needed for evaluation of the therapeutic potential of galectin-9.
Introduction
Galectin-9 is a member of the animal lectin family (galectin family) that is defined by its affinity for lactosamine-type disaccharides and consensus amino acid residues in the carbohydrate recognition domain (CRD) (Barondes et al. 1994) . The protein consists of two CRDs joined by a linker peptide, and thus belongs to the so-called tandem-repeat-type subclass of the family (Hirabayashi and Kasai 1993) . The linker peptide is susceptible to proteolysis due to its disordered structure. Dissociation of the two CRDs through cleavage at the linker region leads to a substantial decrease in the biological activities of tandem-repeat-type galectins. Human galectin-9 was first functionally identified as a T cell-derived eosinophil chemoattractant (Matsumoto et al. 1998) . Subsequent studies; however, established galectin-9 as a multi-functional regulator of innate and adaptive immune responses, especially in T-cell development and homeostasis and inflammation (Hirashima et al. 2004) . Although these findings indicate that galectin-9 is a promising agent for the treatment of immune-related diseases, the proteolytic instability and low solubility of recombinant galectin-9 (<0.2 mg/mL in the case of the most abundant naturally occurring isoform, G9M) are major obstacles for both in vitro and in vivo experiments involving recombinant proteins.
We previously reported the development of a stable form of galectin-9 (G9Null) through truncation of the linker peptide (Nishi et al. 2005) . G9Null is highly stable as to proteolysis and has biological activities comparable with or even higher than those of G9M. G9Null (and in some cases wild-type galectin-9) has been used to demonstrate therapeutic potential in animal models of inflammatory and immune-related diseases (Wiersma et al. in press) including rheumatoid arthritis (Seki et al. 2008) , encephalomyelitis (Zhu et al. 2005) , Type I diabetes (Chou et al. 2009 ), allergic asthma (Niki et al. 2009 ) and sepsis (Tsuboi et al. 2007 ). On the other hand, the structural modification only slightly improved the solubility of the protein. The maximum concentration of G9Null in phosphate buffered saline (PBS) is typically 0.3-0.4 mg/mL. In the previous study, we pointed out the possibility that the N-terminal 12-15 amino acid residues of the C-terminal CRD (CCRD) constitute the functional linker peptide in G9Null, which was confirmed by recent structural studies of galectin-9 (Yoshida et al. 2010) . In the present study, we further modified the remaining linker region of G9Null by truncation and amino acid substitution to increase its solubility.
Results and discussion
Production and solubility of truncation mutants Serial truncation mutants lacking 4-16 amino acid residues at the N-terminal region of G9Null CCRD ( Figure 1A and B) were produced based on X-ray crystallographic studies (Yoshida et al. 2010) and phylogenetic analyses of the galectin family (Houzelstein et al. 2004) , which allowed prediction of the functional linker region of galectin-9. Ten truncation mutant proteins (mC4-mC16) were expressed in Escherichia coli, and efficiently purified by lactose-affinity chromatography ( Figure 1D ). The protein concentrations of the purified preparations in comparison with that of G9Null are summarized in Figure 2A . A bell-shaped histogram with the highest concentration with 10-amino acid deletion (mC10), which was about three times higher than that of G9Null, was obtained. The yield of recombinant protein paralleled the protein concentration in the purified preparation, because the preparation volume was almost constant among the recombinant proteins. The concentrations of 7 of the 10 mutants were higher than that of G9Null. However, in the cases of mC9, mC10 and mC14, a substantial amount of the purified protein became insoluble after storage for 3 months at 4°C. The G9Null concentration in the eluate from lactose-agarose exceeded 2 mg/mL under the expression and purification conditions used. G9Null starts to form insoluble aggregates in the eluate within a few minutes after elution. The insolubilization process seems to be completed during dialysis, because the The protein concentration of the purified preparation (filled column) and the soluble protein fraction after storage (hatched column) of G9Null and truncation mutants. To compare the solubility and yields of G9Null and mutant proteins, expression and purification were carried out under the same conditions for all the proteins as described under Materials and methods. The results represent the mean ± SD of twelve experiments for G9Null and the mean of two experiments for truncation mutants. (B) The antiproliferative effect of G9Null and truncation mutants on Jurkat cells. The viable cell number of an untreated control culture was taken as 100%. The results represent the means ± SD of triplicate measurements. The asterisk shows that the growth-inhibiting activity of the protein is significantly different from that of G9Null at both 0.1 μM and 0.3 μM (P < 0.01, unpaired Student's t-test). (C) β-HEX release inhibition activity assayed using RBL-2H3 cells. β-HEX activity released into the medium was taken as 100%. The filled rectangle shows the activity released in the absence of IgE and antigen. The results represent the mean ± SD of triplicate measurements. The asterisk shows that the β-HEX release-inhibiting activity of the protein is significantly different from that of G9Null at 0.2 μM (P < 0.01). Figure S1 . (D) SDS-PAGE of mutant proteins. Purified preparations of G9Null mutant proteins (3 μg) were electrophoretically separated in SDS/12.6% polyacrylamide gels under reducing conditions. The gels were stained with Coomassie brilliant blue R-250. M, molecular weight marker proteins.
Structurally optimized form of galectin-9 purified preparation of G9Null did not form insoluble material upon storage for at least 1 year (data not shown). The observations described above suggest that the process proceeds more slowly for mC9/10/14 than for G9Null. The mC4 mutant was not used in subsequent experiments due to its low solubility and yield.
Biological activities of truncation mutants
We previously showed that truncation of the linker peptide does not have adverse effects on the biological activities of galectin-9: G9Null is more active than the wild-type galectin-9 isoforms (G9M and G9S) regarding apoptosisinducing activity and eosinophil chemoattractant activity (Nishi et al. 2005) . To determine the effects of further structural modifications (truncation mutations) on their biological activities, we compared the antiproliferative activity and degranulation-inhibiting activity between G9Null and mC6-mC16. The dose-response curves for Jurkat cell growth inhibition (induction of cell death) showed that mC9, mC11 and mC12 have activities significantly higher than that of G9Null ( Figure 2B ). While, truncation of >13 amino acid residues (mC14 and mC16) resulted in significant decreases in their activities. Other truncation mutants (mC6, mC8, mC10 and mC13) have activities comparable with that of G9Null.
Galectin-9 inhibits degranulation of rat basophilic leukemia cells (RBL-2H3 cells) induced by the IgE-antigen complex (Niki et al. 2009 ). This effect is based on the interaction of galectin-9 with the oligosaccharide moiety of IgE, which in turn inhibits the formation of the IgE-antigen complex. Six of the nine mutants (mC8-mC13) depressed degranulation of RBL-2H3 cells as revealed by β-hexosaminidase (β-HEX) release to a significantly higher extent to the case of G9Null, while the activity of mC14 was lower than that of G9Null ( Figure 2C ). The results are consistent with those for the antiproliferative activity toward Jurkat cells except for in the case of mC16. Although the cell surface receptor(s) mediating the antiproliferative action of galectin-9 has not been identified yet, it is postulated that galectin-9 triggers intracellular signal transduction leading to cell death by crosslinking cell-surface glycoprotein(s). On the other hand, a more simple interaction with a soluble protein (IgE) is needed for the inhibition of degranulation. The difference in action mechanism may explain the dissociation of the two activities of mC16.
Production and properties of truncation mutants with amino acid substitution(s)
The N-terminal region of G9Null CCRD subjected to structural modification in this study (TPAIPPMMYPHPAYPMP) is rich in proline residues (7 of 17 residues). Proline residues are recognized as playing a special role in the folding and unfolding of protein molecules (Levitt 1981) . Proline residues facilitate the formation of secondary structure elements such as turns and the polyproline II helix, but typically disfavor helix and β-strand conformations. It is probable that the proline residues in the above-described region affect the interdomain configuration of galectin-9, and consequently intermolecular interactions and solubility. To further improve the solubility of the truncation mutants, we prepared a series of amino acid substitution mutants as to proline residues in the region ( Figure 1C ). We selected mC9-mC12, especially mC10, for amino acid substitution experiments based on their solubility and biological activities. The protein concentrations of substitution mutants with reduced numbers of proline residues, i.e., mC10-1P1A1/1P1A2/1P1A3/3P3A and mC12-2P2A, were decreased compared with those of the respective parental proteins ( Figure 3A) . Notably, substitution of an alanine residue for the carboxy-most proline residue (mC10-1P1A3, mC10-3P3A and mC12-2P2A) resulted in a drastic decrease in the protein concentration. This was not due to insolubilization of the mutant proteins after elution from lactose-agarose but probably due to their low expression levels in E. coli, suggesting that the presence of the proline residue at the beginning of CCRD is indispensable for proper folding of galectin-9. Three substitution mutants, mC10-HPAP, mC10-HPPY and mC11-AP, showed protein concentrations comparable with or higher than those of the respective parental truncation mutants. These substitution mutants remained soluble after 3 months of storage. The protein concentration of mC10-HPPY was about five times higher than that of G9Null. This concentration (1.9 mg/mL; purified preparation) may not be the highest concentration of mC10-HPPY achievable in PBS, because no visible precipitate formed on centrifugation of the dialyzed solution.
Among the three substitution mutants, only mC10-HPPY showed a significantly higher activity than that of G9Null as to Jurkat cell growth inhibition ( Figure 3B ). The activities of mC10-HPAP and mC11-AP were indistinguishable from that of G9Null. On the other hand, all the three mutants depressed degranulation of RBL-2H3 cells more efficiently than G9Null ( Figure 3C ). The biological activities of G9Null are higher than those of wild-type galectin-9 (G9M and G9S) as shown in the previous study (Nishi et al. 2005) . It is presumed that glycoconjugates crosslinked with G9Null can interact more efficiently with each other than those crosslinked with wild-type galectin-9 depending on the spatial arrangement of two CRDs, which results in the increased biological activities of G9Null. This speculation (i.e., the shorter the linker peptide, the higher the activity of galectin-9) may be applicable to some of the mutant proteins, including mC10-HPPY, described in the present study. In addition, the results show that a mutation experiment focusing on proline residues is effective for improving the solubility of truncation mutants without negative effects on their biological activities.
Protease susceptibility of mC10-HPPY G9Null was developed to overcome the protease susceptibility of wild-type galectin-9. For example, >50% of highly purified G9M was degraded within a week during storage at 4°C, possibly due to contaminating bacterial proteases. However, G9Null remained intact for at least 6 months (Nishi et al. 2005) . In addition, G9Null was resistant to exogenously added proteases. mC10-HPPY was examined for proteolytic stability to determine whether structural modification of G9Null could affect it. Degradation of G9S, the most stable wild-type isoform, was evident after 30 min of incubation with elastase and matrix metalloproteinase (MMP)-3 at an enzyme to substrate ratio of 1:100, and most intact G9S disappeared on 2-h incubation confirming our previous results (Nishi et al. 2005) (Figure 4 ). G9Null and mC10-HPPY remained intact after 2-h incubation. As both G9Null and mC10-HPPY were not degraded under the conditions used, we cannot conclude that there is no difference in protease resistance between the two proteins. However, it is rational to conclude that not only G9Null but also mC10-HPPY is practically resistant to proteases. In agreement with these results, mC10-HPPY was stable on storage at 4°C for at least 3 months (data not shown). mC10-HPAP and mC11-AP were also examined for their stability as to elastase and MMP-3. The results were indistinguishable from those for G9Null and mC10-HPPY (data not shown).
In the present study, we aimed to improve the solubility and yield of a protease-resistant form of galectin-9, G9Null, by modifying the N-terminal region of CCRD. This region is assumed to constitute the functional linker peptide remaining in G9Null. Truncation of this region in combination with amino acid substitution(s) resulted in the development of galectin-9 mutant proteins with increased solubility and yield. Among them, mC10-HPPY was found to have the highest Fig. 4 . Protease susceptibility of G9S, G9Null and mC10-HPPY. Recombinant proteins were incubated with elastase (A) or MMP-3 (B) at an enzyme to substrate ratio of 1:100 at 37°C. Aliquots were withdrawn from the reaction mixtures at different times and then subjected to SDS-PAGE. M, molecular weight marker proteins. Structurally optimized form of galectin-9 solubility/yield of about five times higher than those of G9Null. In addition, the biological activities and protease resistance of mC10-HPPY are slightly better than or comparable with those of G9Null. This highly stable and soluble form of galectin-9 (ssGal-9/ssG9) might be a useful agent for both research and therapeutic purposes.
Materials and methods

Construction of expression vectors
The PCR primers used for construction of the expression vectors are shown in Supplementary data Table SI. The G9Null cDNA contains a BamHI site at Position 348. To efficiently construct expression vectors, a single nucleotide substitution (GGATCC → GTATCC) was introduced into G9Null cDNA without an amino acid substitution. The modified G9Null cDNA was used as a target for PCR-based mutagenesis. Expression vectors for the truncation mutants lacking 4-16 amino acid residues at the N-terminal region of CCRD (mC4-mC16, Figure 1B ) were prepared as follows: In two separate reactions, two overlapping cDNA fragments corresponding to the N-and C-terminal halves of mC4-mC16 were amplified using A1 + A2 (common N-terminal CRD, N-terminal carbohydrate recognition domain), and B1-K1 + A4 (CCRDs). The amplified fragments were then mixed and subjected to a second round of PCR using A1 + A4 to generate a full-length cDNA. The amplified cDNA was digested with NdeI and BamHI, and then inserted into the NdeI-BamHI sites of pET-11a (Stratagene, La Jolla, CA). Expression vectors for the mutants with amino acid substitution(s) ( Figure 1C ) were prepared by essentially the same procedure as that described above. The DNA sequences of all the expression vectors were confirmed by automated sequencing.
Expression and purification of recombinant proteins Expression of recombinant proteins in E. coli BL21(DE3) cells was carried out as described previously (Matsushita et al. 2000) except that E. coli was cultured 16 h at 20°C after the addition of isopropyl-β-D-thiogalactopyranoside. To compare the solubility and yields of G9Null and mutant proteins, expression and purification were carried out under the same conditions for all the proteins: recombinant proteins in the E. coli cell extract derived from 400-mL of culture were recovered by batch-wise absorption on 1.5 mL of lactose-agarose gel (J-Oil Mills, Inc., Tokyo, Japan). The gel was packed into a column, and then washed with 15 mL of 20 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 0.03% 3-([3-cholamidopropyl] dimethylammonio)-1-propanesulfonic acid (TBS, 0.03% CHAPS). Recombinant proteins were eluted with 3 mL of TBS, 0.2 M lactose, and then dialyzed against PBS. The dialysate was centrifuged at 25,000 × g for 20 min. The resulting supernatant was sterilized by filtration, and then used as the purified preparation. The purified preparation was stored at 4°C. After 3 months, the preparation was centrifuged as above to remove any insoluble material formed. The resulting supernatant was used as the soluble protein fraction after storage. The protein concentration was determined using bicinchoninic acid protein assay kit (Pierce Biotechnology, Inc., Rockford, IL) and bovine serum albumin (BSA) as a standard.
Cell proliferation assay
The antiproliferative effect on the Jurkat T cell line was determined by means of the WST-8 assay as described previously (Nishi et al. 2008 ). Jurkat cells (5 × 10 4 cells in 90 μL of medium/well) were plated on 96-well plates and then cultured for 2 h. Test samples were added at various concentrations, and then the cultures were continued for 24 h. WST-8 reagent (Cell Counting Kit-8; Dojin Laboratories, Kumamoto, Japan) was added to the culture medium (10 μL/well), followed by incubation for 2 h. Each assay was performed in triplicate. Using an enzyme-linked immunoadsorbent assay autoreader, the viable cell number was determined by measuring the difference between the absorbance at 450 and that at 620 nm.
β-Hexosaminidase release assay
The β-HEX release assay was performed as described previously with modifications (Niki et al. 2009 ). RBL-2H3 cells were inoculated into 96-well plates (2 × 10 4 cells/well). After 24-h culture, cells were washed once with assay buffer (Hanks' balanced salt solution containing 20 mM HEPES-NaOH, pH 7.5, and 1 mg/mL BSA), and then stimulated by the addition of 0.3 μg/mL TIB-141 (anti-2,4,6-trinitrophenyl (TNP) mouse monoclonal IgE) and 0.048 μg/mL TNP-conjugated BSA (TNP-BSA; Biosearch Technologies, Inc., Novato, CA). Galectins were added 10 min before the addition of TIB-141 unless otherwise stated. The culture medium was collected 60 min after the addition of TNP-BSA. After washing with assay buffer, cells were lysed with 0.1% Triton X-100. β-HEX activity in the culture medium and cell lysate was determined. A hybridoma cell line producing TIB-141 was obtained from ATCC.
Protease treatment
Recombinant proteins were first incubated at 37°C for 5 min in digestion buffer. After the addition of a protease, the reaction mixture was incubated for 120 min at 37°C. The total reaction mixture, 600 µL, contained 36 µg of protein sample with an enzyme to substrate ratio of 1:100 (weight ratio). Aliquots were withdrawn from the reaction mixture at different times for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The following digestion buffers were used for elastase and MMP-3, respectively: 0.1 M Tris-HCl (pH 8.0), 0.15 M NaCl, 1 mM CaCl 2 , and 0.05 M Tris-HCl (pH 7.5), 0.15 M NaCl, 10 mM CaCl 2 , 1 µM ZnCl 2 . Activated MMP-3 was prepared as described previously (Nishi et al. 2003) .
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